AR - TechWire

2025.07.18

15:48

Huadong Medicine: HDM2012 for injection obtains drug clinical trial approval notice

Huadong Medicine announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. received the "Notice of Approval for Drug Clinical Trial" issued by the State Drug Administration, and the clinical trial application for HDM2012 for injection submitted by Zhongmei Huadong was approved. HDM2012 for injection is a new antibody-drug conjugate (ADC) targeting human mucin-17 (MUC-17) independently developed by Zhongmei Huadong. It is a monoclonal antibody against MUC-17 and a topoisomerase I inhibitor conjugated by a cleavable linker, with a drug-antibody conjugate ratio (DAR) of 8. This product is a world-first Class 1 biological product, and Zhongmei Huadong owns global intellectual property rights. HDM2012 specifically recognizes MUC-17 positively expressed tumor surface antigens through the targeting effect of antibodies, and uses target antigen-mediated internalization to allow ADC to enter the tumor cells. The linker breaks and releases the toxin drug to exert an anti-tumor effect. At the same time, the bystander effect of HDM2012 also exerts a certain degree of tumor killing effect. Preclinical research results show that HDM2012 has good drugability, safety and effectiveness.

15:36

Maxic: The company has no cooperation with UBTECH and Zhiyuan Robotics

On July 18, Maxicun said on the interactive platform that the company has not yet cooperated with UBTECH and Zhiyuan Robotics, and the company's optical sensor products have been shipped in batches in the field of sweeping robots. The company's optical sensor products have been sent for sample verification in the field of AR/VR/MR smart wearable devices.

15:34

Jiabiyou: Net profit in the first half of 2025 is expected to increase by 57.61% year-on-year

Jiabiyu announced that it achieved operating income of approximately RMB 307 million in the first half of 2025, an increase of 17.59% over the same period last year; net profit attributable to the parent company's owners was approximately RMB 107 million, an increase of 57.61% over the same period last year; net profit attributable to the parent company's owners after deducting non-recurring gains and losses was approximately RMB 93 million, an increase of 75.45% over the same period last year. The increase in the company's operating income during the reporting period was mainly due to the increase in sales of its core products ARA and algae oil DHA; the increase in profits was mainly due to the increase in operating income. At the same time, the company's production efficiency was improved, and the product structure and customer structure were optimized, which improved the company's profitability.

03:40

The U.S. House of Representatives passed the CLARITY Act, which will now move to the Senate for consideration.

2025.07.17

20:10

Potential Fed Chair candidate Warsh says the Fed faces a 'credibility crisis' and the last thing we need is business as usual

Potential Federal Reserve Chairman candidate WARSH said the Fed is facing a "credibility crisis" and the last thing we need is for the Fed to continue with business as usual.

10:47

Johnson, speaker of the U.S. House of Representatives, said that the vote on the GENIUS bill will take place tomorrow and the CLARITY bill may take place next week. He also added that the House of Representatives will include anti-CBDC (central bank digital currency) legislation in the National Defense Authorization Act (NDAA).

08:18

The Third Chain Expo released the "Global Supply Chain Promotion Report" and four major index matrices

The third China International Supply Chain Promotion Expo opened in Beijing yesterday. At the conference, the Global Supply Chain Promotion Report was released simultaneously, and the four major supply chain index matrices were released for the first time, providing a "Chinese solution" for in-depth cooperation in the global supply chain. The report systematically analyzes the latest situation of the global supply chain promotion system in the past year, and summarizes the main practices and latest opportunities that China has made to promote the development of the global supply chain. It also focuses on the latest developments in global cutting-edge technologies and key product research and development, and draws a global supply chain map for six products such as drones, AR glasses and wine. The global supply chain index matrix shows that the overall development of the global supply chain is still relatively stable. From 2018 to 2024, the four index values of promotion, connection, innovation and resilience that constitute the global supply chain index matrix have all increased.

2025.07.15

19:22

According to the Financial Times: Barclays (BARC.L) and UBS (UBS.N) refused to commit to joining the Net Zero Banking Alliance.

12:31

Shanghai: Accelerate the implementation of major engineering projects and build core capabilities of the smart glasses industry

On the morning of July 14, a ceremony was held for the Sunny Optical 12-inch transparent substrate wafer AR glasses micro-nano optical product production line project, a major project in Shanghai, and a strategic cooperation agreement was signed with Shanghai Guotou and Lingang Group. Tang Wenkan, deputy director of the Shanghai Municipal Economic and Information Commission, pointed out in his speech that Shanghai has always attached great importance to the development of the electronic information industry. After years of cultivation, a relatively complete industrial chain has been formed. In recent years, Lingang has gathered a number of high-quality upstream and downstream smart glasses companies such as chips, displays, equipment, and materials. In the next step, Shanghai will continue to go all out to support the electronic information industry. First, strengthen policy guidance. Prepare and release a new round of smart terminal and display action plans, make good use of special funds, and increase support. Second, support technical research. Promote the industrialization of core display technologies such as lightweight, large field of view, full-color optical waveguides, and full-color Micro LEDs. Third, create key products. Support the development of Shanghai brand terminal products in key areas such as AI PCs, AI mobile phones, smart glasses, and robots. Fourth, stimulate the vitality of talents. Through multi-level talent plans, those who are willing to innovate, dare to innovate, and can innovate will have no worries. I hope Sunny Optical can achieve greater development in Shanghai, start production and take effect as soon as possible, lead technological innovation and play a leading role in the industry.

2025.07.14

21:37

US cryptocurrency stocks collectively rose

U.S. cryptocurrency concept stocks rose collectively, with BIT Mining surging more than 25%, SharpLink Gaming rising more than 12%, MARA Holdings rising nearly 8%, CleanSpark rising more than 5%, and Strategy rising more than 4%.

2025.07.10

12:32

Shanghai Pudong: will promote the rapid agglomeration of a number of key parts companies such as reducers, dexterous hands, and controllers

Shanghai held a press conference for the 2025 World Artificial Intelligence Conference and the High-level Meeting on Global Governance of Artificial Intelligence. Li Hui, deputy mayor of Shanghai Pudong New Area, said that in the embodied intelligence track, we should focus on making the "brain" smarter - the National Humanoid Robot Innovation Center has released a large model of generative robot movement, and relevant entities such as Baosight Industrial Brain are constantly strengthening multimodal interaction capabilities and scene applications, which is one of the key areas we will focus on in the future; in the spatial intelligence track, we will focus on making the "eyes" brighter - the leading domestic visual processing chip, the only ultra-large-scale dynamic spatiotemporal data fusion analysis platform in China, and well-known AR glasses will continue to overcome multimodal perception, spatial computing, fusion twins and other cutting-edge technologies in Pudong; in the field of robot body, we will focus on making the "limbs" more flexible - Pudong already has more than ten robot body companies, and next we will promote a number of key component companies such as reducers, dexterous hands, and controllers to gather rapidly in Pudong.

05:18

The ISHARES MSCI Brazil ETF fell 2.2% in after-hours trading after U.S. President Trump announced the tariff measures.

2025.07.09

23:33

Poland buys 18 coastal radar systems to strengthen sea and air defenses

On July 9, local time, the Polish Ministry of Defense announced that it had signed a contract worth 430 million zlotys (about 850 million yuan) with the Polish-Israeli consortium (composed of Polish KenBIT and Israeli ELTA Systems) to purchase 18 ELM-2238X STAR-X radar systems, which are scheduled to be delivered from 2027 to 2030. The radar system will be deployed on the Polish coast to monitor maritime and low-altitude targets. Polish Defense Minister Kosiniak-Kamysz said that the radar has three-coordinate detection capabilities, can track multiple sea and air targets at the same time, and cooperate with the Polish Navy's existing and future combat units (such as new frigates) to achieve 24-hour monitoring and enhance threat identification and deterrence capabilities.

18:01

Market news: Arm (ARM.O) said the number of its data center customers has increased 14 times to 70,000 since 2021.

2025.07.08

16:47

Qianyuan Pharmaceutical: Subsidiary obtains approval for Ebastine chemical raw material drug listing

Qianyuan Pharmaceutical announced that its subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. received the "Notice of Approval of the Application for Marketing of Chemical APIs" for Ebastine issued by the State Drug Administration. Ebastine is suitable for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria with or without allergic conjunctivitis. The original developer of Ebastine is INDUSTRIAS FARMACEUTICAS ALMIRALL, SA. The Ebastine tablets of its subsidiary Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. have passed the consistency evaluation and have been included in the Class B National Medical Insurance Catalog. After the Ebastine API is approved for marketing, it will further reduce the production cost of the preparation products and enhance the market competitiveness of the products.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Oppenheimer: Raises Nvidia (NVDA.O) price target from $175 to $200.
                            2025-07-15

                                    Shanghai: Accelerate the implementation of major engineering projects and build core capabilities of the smart glasses industry
                            2025-07-15

                                    ETF Midday Review: ChiNext Artificial Intelligence ETF Southern led the gains by 4.95%, while the CSI 2000 ETF Fund led the losses by 4.36%
                            2025-07-15

                                    Tesla Model Y long-range rear-wheel drive version is priced at about RMB 567,000 in India
                            2025-07-15

                                    BOE A: Will submit a review to the ITC regarding the preliminary ruling of the 337 investigation on trade secrets
                            2025-07-15